# ADR-M14.5 — Public launch and development pause baseline

**Date:** 2026-09-07
**Status:** Accepted for the M1–M14.5 closure baseline

## Decision

Close the M1–M14.5 implementation cycle and pause development for real-world observation. Launch the static public site on the current temporary origin when the explicit production SEO verification passes. Keep `lina.vet` migration as R1, external channels and public analytics as R2, and production compliance/Intake obligations as R3.

Production D1 may be provisioned and migrated while empty and fail-closed. The private Office/Intake plane must remain protected/disabled until its external Access, identity, notification, and privacy evidence gates are complete.

The PMR Article 22 prerequisite is unresolved and deferred. The owner override accepts public launch with notification evidence deferred. The project must not claim legal compliance or enable real public Intake on that basis.

M15 and M16 are future evidence-review milestones only. They are not started, scheduled, or authorized by this ADR. No `v1.0.0` product release tag is created; the closure checkpoint uses `m14.5-pause-2026-09-07`.

## Consequences

- The temporary origin may be indexable, but it is not the permanent SEO identity.
- Public analytics stays off unless a verified owner-controlled provider/domain is supplied.
- Private M14.5 telemetry remains physically separate from public analytics and cannot contain PII, clinical text, drug names, IDs, request IDs, or raw bodies.
- Observation has no start date until the first genuine production `REAL` event after protected Office activation.
- Restarting development requires an explicit milestone request and the pause/restart gates.
